Dake Benjamin T. - 16 Aug 2022 Form 4 Insider Report for Aerovate Therapeutics, Inc. (JBIO)

Role
Officer Title: President, Chief Operating Officer and Secretary
Signature
/s/ George A. Eldridge, Attorney-in-Fact
Issuer symbol
JBIO
Transactions as of
16 Aug 2022
Net transactions value
-$446,392
Form type
4
Filing time
18 Aug 2022, 17:00:16 UTC
Previous filing
12 Aug 2022
Next filing
08 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVTE Common Stock Options Exercise $36,540 +21,000 $1.74* 21,000 16 Aug 2022 Direct F1
transaction AVTE Common Stock Sale $235,034 -10,475 -50% $22.44 10,525 16 Aug 2022 Direct F1, F2
transaction AVTE Common Stock Sale $164,724 -7,074 -67% $23.29 3,451 16 Aug 2022 Direct F1, F3
transaction AVTE Common Stock Sale $83,174 -3,451 -100% $24.10 0 16 Aug 2022 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -3,189 -17% $0.000000 15,394 16 Aug 2022 Common Stock 3,189 $1.74 Direct F1, F5
transaction AVTE Stock Option (Right to Buy) Options Exercise $0 -17,811 -25% $0.000000 54,514 16 Aug 2022 Common Stock 17,811 $1.74 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.92 to $22.915, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.94 to $23.94, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.95 to $24.57, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F6 A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.

Remarks:

Officer Title: President, Chief Operating Officer and Secretary